UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2017

 

 

NantHealth, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37792   27-3019889

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

9920 Jefferson Blvd

Culver City, California 90232

(Address of principal executive offices)(Zip Code)

(310) 883-1300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

We held our 2017 annual meeting of stockholders on June 13, 2017 (the “Annual Meeting”). Of the 121,626,567 shares of our common stock outstanding as of the record date of April 17, 2017, 96,367,538 shares of common stock were represented at the Annual Meeting, either in person or by proxy, constituting approximately 79.2% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

 

  1. Election of Directors. Each of the following nominees was elected to serve as a director, to hold office until our 2018 annual meeting of stockholders and until his respective successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal, based on the following results of voting:

 

Nominee

   Votes For      Votes Withheld      Broker Non-Votes  

Patrick Soon-Shiong, M.D.

     90,998,883        1,049,465        4,319,190  

Michael S. Sitrick

     91,153,372        894,976        4,319,190  

Kirk K. Calhoun

     91,186,536        861,812        4,319,190  

Mark Burnett

     91,182,436        865,912        4,319,190  

Michael Blaszyk

     91,182,836        865,512        4,319,190  

 

  2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017 was ratified based on the following results of the voting:

 

Votes For      Votes Against      Abstentions      Broker Non-Votes  
  96,331,082        34,743        1,713        —    


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

NantHealth, Inc.
By:   /s/ Paul Holt
  Paul Holt
  Chief Financial Officer

Date: June 14, 2017